Kura Oncology (KURA) Expected to Announce Earnings on Thursday

Kura Oncology (NASDAQ:KURA - Get Free Report) is expected to announce its Q1 2025 earnings results after the market closes on Thursday, May 1st. Analysts expect Kura Oncology to post earnings of ($0.56) per share and revenue of $39.08 million for the quarter.

Kura Oncology (NASDAQ:KURA - Get Free Report) last issued its earnings results on Wednesday, February 26th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.65) by $0.43. The company had revenue of $53.88 million during the quarter, compared to analyst estimates of $57.96 million. On average, analysts expect Kura Oncology to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Kura Oncology Price Performance

Shares of KURA stock remained flat at $6.43 during trading on Friday. 984,566 shares of the stock traded hands, compared to its average volume of 1,149,473. The company has a market capitalization of $519.40 million, a price-to-earnings ratio of -2.72 and a beta of 0.83. Kura Oncology has a 1 year low of $5.41 and a 1 year high of $23.48. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47. The firm's 50-day moving average price is $6.88 and its two-hundred day moving average price is $9.99.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. StockNews.com raised shares of Kura Oncology from a "hold" rating to a "buy" rating in a research note on Friday, April 4th. HC Wainwright reissued a "buy" rating and issued a $40.00 target price on shares of Kura Oncology in a research report on Thursday, February 27th. Wedbush restated an "outperform" rating and set a $36.00 price target on shares of Kura Oncology in a research report on Tuesday, April 8th. UBS Group dropped their price objective on Kura Oncology from $27.00 to $14.00 and set a "buy" rating for the company in a research note on Thursday, March 6th. Finally, BTIG Research lowered Kura Oncology from a "buy" rating to a "neutral" rating in a research note on Thursday, February 6th. Three analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $25.50.

Insider Buying and Selling

In related news, SVP Thomas James Doyle sold 4,949 shares of Kura Oncology stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $38,948.63. Following the sale, the senior vice president now directly owns 88,193 shares in the company, valued at $694,078.91. This trade represents a 5.31 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Mollie Leoni sold 4,963 shares of the company's stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $39,058.81. Following the completion of the transaction, the insider now owns 88,253 shares of the company's stock, valued at $694,551.11. This represents a 5.32 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 11,729 shares of company stock worth $92,307 over the last 90 days. 6.40% of the stock is owned by insiders.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.